PDCD1 and neoplasm: Combining CD73 inhibitors with both anti-CTLA-4 and anti-PD1 antibodies significantly increased the effect of immunotherapy through an increased frequency of tumor-infiltrating CD8+ T cells, suppressed Treg accumulation within tumor tissues in murine melanoma models, and enhanced T cell responses [200,201].